anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
MAIA Biotechnology · pitchdeck

MAIA Biotechnology | Investor Presentation Deck | 39 slides

39 pages · 5 arc beats · 3 loops

Pitchdeck Download JSON
Unlock

MAIA Biotechnology | Investor Presentation Deck | 39 slides

MAIA Biotechnology · 2023-11
arc beats above · slides in the middle · loops below · scroll → 3 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

5
coverage by narrative range · generated from this deck JSON
Narrative range 21 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 2 slides 100% 2/2 slides 100% 2/2 slides · 10 hits
— 0/2 slides
— 0/2 slides
50% 1/2 slides 100% 2/2 slides · 3 hits 100% 2/2 slides Solution 5 slides 100% 5/5 slides 100% 5/5 slides · 22 hits
— 0/5 slides
20% 1/5 slides
— 0/5 slides
100% 5/5 slides · 8 hits 20% 1/5 slides Market Size 2 slides 100% 2/2 slides 100% 2/2 slides · 7 hits
— 0/2 slides
— 0/2 slides
— 0/2 slides
100% 2/2 slides · 4 hits
— 0/2 slides
Traction 11 slides 100% 11/11 slides 100% 11/11 slides · 46 hits
— 0/11 slides
36.4% 4/11 slides · 5 hits 18.2% 2/11 slides 100% 11/11 slides
— 0/11 slides
Team 1 slides 100% 1/1 slides 100% 1/1 slides · 8 hits
— 0/1 slides
— 0/1 slides
— 0/1 slides
100% 1/1 slides
— 0/1 slides

Slide inventory

39
every slide · same image gating as the playbook
01
Slide 1
front_matter
Open slide detail
02
other
Open slide detail
03
other
Open slide detail
04
The slide outlines the status of THIO-101, 102, and 103 trials and mentions specific patent filings.summarize
Open slide detail
05
The slide uses a Gantt-style layout to represent drug development stages.plan_implementation
Open slide detailBeat · ProblemLoop · Cost Of Inaction
06
The slide uses a chromosome icon for the lead asset and a fast-forward icon for the pipeline strategy.present_solution
Open slide detailBeat · ProblemLoop · Cost Of Inaction
07
transition
Open slide detailBeat · Solution
08
The slide uses a visual comparison of population growth to frame the problem of age-related cancer.size_opportunity
Open slide detailBeat · Solution
09
This slide serves as a transition or key message reinforcement.establish_context
Open slide detailBeat · Solution
10
The slide illustrates the interaction between THIO (telomere targeting) and standard checkpoint inhibitor therapies.present_solution
Open slide detailBeat · Solution
11
This slide serves as a validation/traction point by highlighting a partnership with a major pharmaceutical company.show_traction
Open slide detailBeat · Traction
12
The chart shows tumor volume over time, highlighting the efficacy of the THIO + Atezo combination compared to controls.present_solution
Open slide detailBeat · Traction
13
The slide outlines a multi-part clinical trial process (Part A, Part B, and Expansion) for NSCLC 2L patients.show_traction
Open slide detailBeat · Traction
14
The table compares Cyramza+Docetaxel, Docetaxel alone, and THIO+Libtayo across efficacy, safety, and administration metrics.compare_peers
Open slide detailBeat · Traction
15
The slide compares the safety profile of THIO against standard of care (SOC) chemotherapy.analyze_data
Open slide detailBeat · Traction
16
DCR stands for Disease Control Rate. The table compares historical benchmarks (Standard of Care) against the company's clinical trial results (THIO-101).compare_peers
Open slide detailBeat · Traction
17
Data presented in a table format with footnotes explaining the methodology for DCR calculation.show_traction
Open slide detailBeat · Traction
18
DCR = Disease Control Rate. Data shows high efficacy across all tested dose levels.analyze_data
Open slide detailBeat · Traction
19
Clinical trial data visualization showing patient-level outcomes over time.analyze_data
Open slide detailBeat · Traction
20
The chart tracks individual patient outcomes over time, including treatment status, response type, and study exit reasons.analyze_data
Open slide detailBeat · Traction
21
The plot highlights long-term benefit post-therapy and low mortality rates in the cohort.show_traction
Open slide detailBeat · Traction
22
The slide provides visual and quantitative evidence of the drug's mechanism of action (MOA) by showing the increase of TIFs over 72 hours.present_solution
Open slide detail
23
The slide outlines a multi-stage clinical trial design (Part A/B to Part C) involving immune activation with various checkpoint inhibitors.plan_implementation
Open slide detailLoop · Quick Win Big Bet
24
Includes two line charts showing tumor volume reduction and rechallenge success.show_traction
Open slide detailLoop · Quick Win Big Bet
25
The slide compares clinical trial data for three different treatment regimens in CRC patients.compare_peers
Open slide detailLoop · Quick Win Big Bet
26
The table compares historical standard of care data against planned THIO-102 trial outcomes.compare_peers
Open slide detailLoop · Quick Win Big Bet
27
The table compares an existing standard of care (Zepzelca) against the company's planned trial (THIO-102).compare_peers
Open slide detailLoop · Quick Win Big Bet
28
The slide presents two line charts showing tumor volume reduction over time for different treatment regimens in SCLC and HCC models.show_traction
Open slide detailLoop · Quick Win Big Bet
29
The chart shows tumor volume over time, with the THIO group reaching 100% complete response (CR).show_traction
Open slide detailLoop · Quick Win Big Bet
30
The slide shows two line charts representing tumor volume over time in HCC models, highlighting the efficacy of THIO and THIO+Libtayo combinations.show_traction
Open slide detailLoop · Quick Win Big Bet
31
The slide outlines a clinical trial process flow from initial baskets through immune activation to a pivotal phase.plan_implementation
Open slide detailLoop · Quick Win Big Bet
32
The slide outlines both regulatory exclusivity (NCE) and patent protection (issued/pending) to establish a competitive moat.present_solution
Open slide detail
33
other
Open slide detailBeat · Team
34
The slide includes specific details on options, warrants, and insider ownership percentages.analyze_data
Open slide detail
35
transition
Open slide detail
36
The chart compares the combined market size of major CPIs ($42B) against Libtayo ($0.5B) to illustrate the growth potential.size_opportunity
Open slide detailLoop · Pareto Focus
37
The slide uses a table-like layout to associate logos with market cap figures, followed by specific acquisition deal context.compare_peers
Open slide detailLoop · Pareto Focus
38
The slide uses a growth curve background to imply value accumulation over time.plan_implementation
Open slide detail
39
The slide serves as a milestone marker for the company's public listing.show_traction
Open slide detail